Compass Therapeutics (NASDAQ:CMPX) Stock Rating Lowered by Wall Street Zen

Posted by Geri Gentry on Aug 10th, 2026

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday.

A number of other equities research analysts also recently issued reports on the stock. Raymond James Financial downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 28th. HC Wainwright reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Compass Therapeutics in a research note on Monday, April 27th. Citizens Jmp reaffirmed a “market outperform” rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Tuesday, April 28th. Citigroup reiterated a “market outperform” rating on shares of Compass Therapeutics in a research report on Thursday, June 4th. Finally, LADENBURG THALM/SH SH initiated coverage on Compass Therapeutics in a report on Wednesday, July 1st. They issued a “buy” rating and a $5.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.77.

Get Our Latest Stock Analysis on CMPX

Compass Therapeutics Price Performance

Shares of CMPX opened at $2.15 on Friday. Compass Therapeutics has a 52-week low of $1.61 and a 52-week high of $6.88. The company has a 50-day simple moving average of $2.09 and a 200-day simple moving average of $3.85. The company has a market capitalization of $387.19 million, a PE ratio of -5.37 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, research analysts anticipate that Compass Therapeutics will post -0.43 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CMPX. Russell Investments Group Ltd. increased its position in Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after buying an additional 7,592 shares in the last quarter. Parallel Advisors LLC purchased a new stake in shares of Compass Therapeutics in the first quarter valued at $28,000. Creative Planning purchased a new stake in shares of Compass Therapeutics in the second quarter valued at $30,000. State of Wyoming acquired a new stake in shares of Compass Therapeutics during the second quarter valued at $31,000. Finally, Flagship Harbor Advisors LLC acquired a new stake in shares of Compass Therapeutics during the fourth quarter valued at $32,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

(Get Free Report)

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.